LENZ — LENZ Therapeutics, Inc.
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2021-06-25.
Performance
Technicals
Others in Healthcare
Measured signals that fired on LENZ
| date | signal | measured base rate |
|---|---|---|
| 2026-06-09 | Equal lows taken out structure | -0.64% over 21 days · t = -4.75 · n = 55,661 statistically distinguishable from its control group |
| 2026-05-18 | Equal lows taken out structure | -0.64% over 21 days · t = -4.75 · n = 55,661 statistically distinguishable from its control group |
| 2026-04-24 | Fair value gap, bearish structure | -0.45% over 21 days · t = -3.29 · n = 108,591 statistically distinguishable from its control group |
| 2026-03-30 | Cluster buy: three or more insiders insider | +0.63% over 21 days · t = 1.84 · n = 3,050 not distinguishable from its control group |
| 2026-03-30 | Conviction buy by an officer insider | -1.03% over 21 days · t = -2.24 · n = 1,083 statistically distinguishable from its control group |
| 2026-03-09 | Equal lows taken out structure | -0.64% over 21 days · t = -4.75 · n = 55,661 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-03-27 | Schimmelpennink Evert B. President, CEO and Secretary | Open-market purchase | 28.1K | 8.95 | 251.4K |
| 2026-03-27 | Chevallard Daniel R. Chief Financial Officer | Open-market purchase | 7.5K | 8.57 | 64.3K |
| 2026-03-27 | George Jeffrey P. Director | Open-market purchase | 5.6K | 8.92 | 49.9K |
| 2025-11-17 | Olsson Shawn Chief Commercial Officer | Open-market sale 10b5-1 plan | 5.8K | 26.37 | 152.6K |
| 2025-11-17 | Olsson Shawn Chief Commercial Officer | Open-market sale 10b5-1 plan | 4.2K | 25.74 | 108.4K |
| 2025-11-17 | Olsson Shawn Chief Commercial Officer | Option exercise 10b5-1 plan | 10.0K | 2.08 | 20.8K |
| 2025-11-07 | MCCOLLUM JAMES W Director | Open-market purchase | 10.5K | 22.79 | 239.3K |
| 2025-11-07 | Chevallard Daniel R. Chief Financial Officer | Open-market purchase | 2.2K | 22.76 | 49.6K |
| 2025-11-07 | Chevallard Daniel R. Chief Financial Officer | Open-market purchase | 20 | 22.71 | 454 |
| 2025-09-30 | Versant Venture Capital VI, L.P. | Open-market sale | 83.1K | 46.41 | 3.9M |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 38.2M | 4.2M |
| Alpha Wave Global, LP | 33.1M | 3.6M |
| FMR LLC | 32.9M | 3.6M |
| Versant Venture Management, LLC | 24.3M | 2.7M |
| BlackRock, Inc. | 18.1M | 2.0M |
| Squarepoint Ops LLC | 13.8M | 1.5M |
| Aberdeen Group plc | 10.6M | 1.2M |
| FRANKLIN RESOURCES INC | 10.1M | 1.1M |
| VANGUARD CAPITAL MANAGEMENT LLC | 9.5M | 1.0M |
| 72 Investment Holdings, LLC | 9.3M | 1.0M |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- LENZ Therapeutics (LENZ) Q2 2026 Earnings Call Transcript · 2026-08-19
- Why is LENZ Therapeutics stock rallying today? · 2026-08-12
- Lenz Therapeutics, Inc. (LENZ) filed form 8-K · 2026-08-11 · SEC EDGAR
Ask the AI about LENZ
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →